| Literature DB >> 29302628 |
M Nooshadokht1,2, I Sharifi3, M A Mohammadi4, M Pirestani5, A Afgar4, A Mahootchi1, S Salari6.
Abstract
BACKGROUND ANDEntities:
Keywords: Immunocompetent individuals; Immunocompromised patients; Iran; Microsporidia
Year: 2017 PMID: 29302628 PMCID: PMC5747587 DOI: 10.18869/acadpub.cmm.3.1.30
Source DB: PubMed Journal: Curr Med Mycol ISSN: 2423-3420
Figure 1Modified trichrome staining of Enterocytozoon bieneusi spores isolated from the stool samples; 1000x magnification
Figure 2Agarose gel electrophoresis (2%) of random PCR products (127 bp). Lane 1: negative control; lane 2: positive control; lane 3: PCR products of positive samples; lane M: 100-bp DNA ladder
The frequency of E.bieneusi in the participants based on their immune status and age
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 0.287 | 2.10 | 17.16 | 33.57 | 67 | Negative | Immunocompetent |
| - | - | 15 | 1 | Positive | ||
| 0.326 | 2.47 | 20.30 | 41.06 | 50 | Negative | Cancer-positive |
| 8.16 | 24.47 | 33.56 | 9 | Positive | ||
| 0.84 | 1.23 | 9.72 | 39.838 | 62 | Negative | HIV/AIDS-positive |
| 2.66 | 8.40 | 40.50 | 10 | Positive |
SD: Standard deviation; SEM: Standard Error of Mean; Significant difference at P<0.05
The frequency of E.bieneusi in the participants based on their clinical symptoms
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| 0.002* | 1.70 21.17)) | 1 | 3(3.2%) | 92(96.8%) | 95(100%) | Negative | Diarrhea |
| 5.99 | 17(16.3%) | 87(83.7%) | 104(100%) | Positive | |||
| 20(10.1%) | 179(89.9%) | 199(100%) | Total | ||||
| 0.002* | 1.67 16.11)) | 1 | 4(3.8%) | 101(96.2%) | 105(100%) | Negative | Abdominal pain |
| 5.18 | 16(17%) | 78(83%) | 94(100%) | Positive | |||
| 20(10.1%) | 179(89.9%) | 199(100%) | Total | ||||
| 0.509 | 0.539 3.47)) | 1 | 11(8.9%) | 112(91.1%) | 123(100%) | Negative | Vomiting |
| 1.37 | 9(11.8%) | 67(88.2%) | 76(100%) | Positive | |||
| 20(10.1%) | 179(89.9%) | 199(100%) | Total | ||||
Significant difference at P<0.05
The frequency of E.bieneusi in the participants based on gender
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| 0.471 | 36(100) | 0(0) | 36(100) | Female | Immunocompetent |
| 32(100) | 1(3.1) | 31(96.9) | Male | ||
| 68(100) | 1(1.5) | 67(98.5) | Total | ||
| 0.999 | 21(100) | 3(14.3) | 18(85.7) | Female | Cancer-positive |
| 38(100) | 6(15.8) | 32(84.2) | Male | ||
| 59(100) | 9(15.3) | 50(84.7) | Total | ||
| 0.998 | 26(100) | 4(15.4) | 22(84.6) | Female | HIV/AIDS-positive |
| 46(100) | 6(13) | 40(87) | Male | ||
| 72(100) | 10(13.9) | 62(86.1) | Total | ||
Significant difference at P<0.05